Quoin Pharmaceuticals and ER-Kim have expanded their exclusive distribution agreement for the former’s investigational therapy, QRX003, to treat Netherton Syndrome.

QRX003 is being developed as a potential therapy to treat Netherton Syndrome, a rare, hereditary skin disorder that is caused by a mutation in the SPINK5 gene (serine protease inhibitor, Kazal Type 5).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is a once-daily topical lotion that includes a broad-spectrum serine protease inhibitor, formulated with the Invisicare delivery technology.

Initially, the companies entered into an exclusive distribution agreement for QRX003 last month.

Under the deal, ER-Kim secured exclusive rights to market QRX003 in 15 countries that included Slovakia, Bosnia & Herzegovina, Hungary, Kosovo, North Macedonia, Romania, Albania, Bulgaria, Montenegro, Croatia, Czechia, Moldova, Poland, Serbia, and Slovenia.

Now, the company gained the rights to commercialise the therapy in six additional countries that include Cyprus, Azerbaijan, Turkey, Georgia, Greece, and Malta.

Quoin Pharmaceuticals CEO Michael Myers said: “We are extending our agreement with ER-Kim, a leading commercial partner for global biotech and pharma, with the addition of six new countries to the territory they have the rights to.

“The expansion of our partnership with Er-Kim will facilitate more streamlined and effective commercialisation of QRX003 in the region, once approval has been obtained.

“Quoin now has 60 countries under partnership distribution agreements for QRX003, which has the potential to become the first approved treatment for Netherton Syndrome.”

QRX003 is being developed for additional rare disease indications in addition to Netherton Syndrome.

No approved therapeutic treatments are available for Netherton Syndrome currently.